A phase 1 randomized, blinded, placebo-controlled safety and acceptability study of the UC-781 vaginal microbicide gel formulation applied rectally in HIV-1 seronegative adults

Trial Profile

A phase 1 randomized, blinded, placebo-controlled safety and acceptability study of the UC-781 vaginal microbicide gel formulation applied rectally in HIV-1 seronegative adults

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs UC 781 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 May 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 28 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top